drugset / Trial / NCT06238921
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
Phase 1/2
Recruiting
31 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Gilead Sciences · collab
NaSequentialOpen-labelTreatment
Summary
This is a Phase I/II Study to determine the safety and efficacy of Sacituzumab Govitecan and Zimberelimab with stereotactic radiation (SRS) in participants with metastatic triple negative breast cancer with brain metastases, compared to treatment with Sacituzumab Govitecan alone.
Timeline
- Start
- 2024-12-19
- Primary completion
- 2027-02
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sacituzumab Govitecan | Monoclonal antibody | 10 mg/kg | — |
| Subject | Zimberelimab | Monoclonal antibody | 360 mg | Intravenous |